효모 독성 및 억제기 스크린을 사용하여 세균 효과 단백질에 의해 표적으로 한 호스트 통로의 확인

Executive Industry Relevance

Identifying host pathways manipulated by bacterial effector proteins is critical for de-risking target validation in anti-infective discovery. Yeast toxicity and suppressor screens provide a functional, phenotype-driven approach to pinpoint dysregulated host biology when traditional binding assays fail. This enables mechanistic insight into pathogen virulence factors, supporting early-stage target confidence and portfolio prioritization for intracellular pathogens.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by linking effector toxicity to specific host pathways through suppressor identification.
• Operational Value: Enables functional target validation when effector proteins lack detectable binding partners or interact with multifunctional host proteins.
• Predictive Value: Supports mechanistic de-risking by revealing pathway-level perturbations rather than isolated protein interactions.

Screening & Assay Development

• Assay Readiness: Generates validated yeast strains expressing effector proteins for reproducible toxicity screening.
• Quantitative Output: Measures growth defect magnitude (e.g., two- to three-log reduction) as a threshold for proceeding to suppressor screens.
• Scalability: Uses 96-well formats and serial dilution spotting for high-throughput suppressor clone evaluation.

Translational & Preclinical Research

• Disease Relevance: Applies to intracellular pathogens like Chlamydia trachomatis, Legionella pneumophila, and Coxiella burnetii, supporting translational biomarker alignment.
• Preclinical Continuity: Identifies host factors that, when suppressed, rescue effector toxicity, enabling follow-up validation via pull-downs, colocalization, or knockout studies.
• Risk-Adjusted Advancement: Focuses efforts on effectors with confirmed pathway modulation, reducing late-stage biological attrition.

Pipeline & Workflow Integration

The method fits within early discovery to inform lead identification by connecting effector expression to host pathway disruption, enabling data-driven target selection.

• Discovery Biology: Supports hypothesis testing by linking effector expression to growth defects in yeast, indicating pathway interference.
• Screening: Delivers assay-ready toxic strains and suppressor libraries for identifying host factors that rescue phenotype.
• Analytics: Provides quantitative growth readouts on selective media to compare effector toxicity and suppressor efficacy.
• Translational Research: Connects yeast-identified suppressors to mammalian homologs for preclinical validation in disease-relevant systems.
• Enterprise Reuse: Establishes a reusable platform for screening effector libraries across multiple intracellular pathogens.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in target validation through functional pathway interrogation.
• Operational Value: Standardized toxicity and suppressor screening workflows with defined growth thresholds.
• Strategic Value: Improved go/no-go decisions by filtering effectors lacking measurable host pathway impact.
• Portfolio Impact: Risk-adjusted prioritization of effector targets based on validated pathway modulation.

Implementation Considerations

• Requires expertise in yeast molecular cloning, galactose-inducible expression, and plasmid library transformation.
• Dependent on instrumentation for sterile culture handling, centrifugation, and incubation at 30°C with shaking.
• Necessitates cross-team standardization of media preparation, plate spotting, and toxicity scoring criteria.
• Adaptation considerations include promoter compatibility, effector toxicity thresholds, and suppressor validation in mammalian systems.
• Practical limitations include the need for large volumes of media and plates, and potential false negatives if effector expression is toxic to yeast library strains.

Biopharma FAQs